Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

BACKGROUND: From 2019 to 2021, Rwandan residents of the border with the Democratic Republic of the Congo were offered the Ad26.ZEBOV (adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein) and MVA-BN-Filo (modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyombayire, Julien, Ingabire, Rosine, Magod, Ben, Mazzei, Amelia, Mazarati, Jean-Baptiste, Noben, Jozef, Katwere, Michael, Parker, Rachel, Nsanzimana, Sabin, Wall, Kristin M, Sayinzoga, Felix, Tichacek, Amanda, Robinson, Cynthia, Hammoud, Niina, Priddy, Frances, Allen, Susan, Karita, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833427/
https://www.ncbi.nlm.nih.gov/pubmed/35776140
http://dx.doi.org/10.1093/infdis/jiac283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833427/
https://www.ncbi.nlm.nih.gov/pubmed/35776140
http://dx.doi.org/10.1093/infdis/jiac283

Ejemplares similares